Physician profile
Abid Mohiuddin
NPI 1063526614
$2,757.96
in general payments reported to CMS, 2019-2025
44 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $12.37 · 2021: $579 · 2022: $633 · 2023: $994 · 2024: $129 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.34 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $631.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $176.90 | 2019-2025 | Imfinzi |
| Pfizer INC. | $141.61 | 2021-2025 | |
| Genzyme Corporation | $127.33 | 2021-2025 | |
| Sobi, INC | $126.49 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $120.33 | 2022-2023 | Imbruvica, Epkinly |
| Coherus Oncology, INC. | $109.45 | 2021-2022 | |
| Glaxosmithkline, LLC. | $100.59 | 2021-2022 | |
| Beigene USA, INC. | $86.40 | 2023 | Brukinsa |
| Amgen INC. | $86.19 | 2022-2023 | Vectibix, Xgeva, Nplate |
| E.R. Squibb & Sons, L.L.C. | $79.02 | 2019-2023 | Opdivo |
| Janssen Biotech, INC. | $65.68 | 2021-2023 | Darzalex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.44 | 2021-2023 | Gilotrif |
| Seagen INC. | $60.54 | 2019-2023 | Tukysa |
| Rigel Pharmaceuticals, INC. | $57.05 | 2023 | Tavalisse, Rezlidhia |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $56.87 | 2021-2023 | Xpovio |
| Ipsen Biopharmaceuticals, INC | $54.25 | 2023 | Tazverik, Onivyde, Somatuline Depot |
| Genentech, INC. | $49.95 | 2021 | |
| Exelixis INC. | $41.50 | 2019-2023 | Cabometyx |
| Array Biopharma INC | $40.62 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Cti Biopharma Corp. | $39.86 | 2023 | Vonjo |
| Emd Serono, INC. | $38.15 | 2023-2024 | Bavencio |
| Celgene Corporation | $32.92 | 2021-2023 | |
| Dendreon Pharmaceuticals LLC | $26.83 | 2023 | Provenge |
| Regeneron Healthcare Solutions, INC. | $24.74 | 2023 | Libtayo |
| Lilly USA, LLC | $23.83 | 2025 | Verzenio, Jaypirca |
| Incyte Corporation | $22.03 | 2025 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $21.99 | 2023 | |
| Novocure INC. | $20.47 | 2025 | Optune Gio |
| Caris Mpi, INC. | $19.78 | 2025 | Mi Cancer Seek |
| Eisai INC. | $17.96 | 2021 | |
| Azurity Pharmaceuticals, INC. | $17.43 | 2025 | Danziten, Vivimusta |
| Adc Therapeutics America, INC. | $16.75 | 2021 | |
| Beone Medicines USA, INC. | $16.54 | 2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $16.53 | 2024 | Pyrukynd |
| Global Blood Therapeutics, INC. | $16.28 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.15 | 2021 | |
| Pharmaessentia USA Corporation | $15.62 | 2023 | Besremi |
| Epizyme, INC. | $15.58 | 2021 | |
| Genentech USA, INC. | $13.67 | 2021 | |
| Kite Pharma, INC. | $13.54 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.00 | 2019 | |
| Merck Sharp & Dohme LLC | $12.37 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abid Mohiuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.